Scientists have identified two specific types of brain cells that behave differently in people with depression, offering a ...

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...

Recent neuroscience research has uncovered biological markers tied to stress, depression, and the gut-brain connection, alongside new insights into sleep regulation and learning mechanisms. These ...

Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...

A new study reveals how chronic pain triggers depression through structural changes in the brain's hippocampus.

Is brain imaging overlooking the truth? Research shows that "weak" brain connections predict behavior as well as top signals, ...

Rates of depression and stress-related disorders rise among new fathers a year after birth, even though they have fewer mental health diagnoses during pregnancy and the first few months after birth.

AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the primary focus, its neuroscience segment is expected to contribute ...